Golden rules for registrars
Medico-legal adviser Dr Jim Rodger offers some expert advice on how to excel as a GP registrar. Read more
In November, NICE decided to delay its draft lipid modification advice, due last month, so that the guideline development group could consider the value of QRISK.
Issued this week, the NICE draft guideline now states that 'emerging evidence suggests that QRISK gives a better estimation of risk in the general population than the Framingham equations'.
Developed from the EMIS records of 529 GP practices, QRISK incorporates a logarithm of age, ratio of serum total to HDL cholesterol, systolic BP, BMI, family history of cardiovascular disease, smoking status, Townsend deprivation score and use of one or more BP treatments.
West London GP Dr Sarah Jarvis, a member of the Primary Care Cardiovascular Society, said: 'It is a welcome move as Framingham is outdated. It was not developed for the UK and is not representative of the UK population that GPs treat.'
NICE draft lipid modification 2008
Comment below and tell us what you think
Quick search - use * for an abbreviated search, eg nico*
Medico-legal adviser Dr Jim Rodger offers some expert advice on how to excel as a GP registrar. Read more
Dr Kingsley Poole describes the differences he experienced working at a remote practice in New Zeala... Read more
Most people feel nervous facing an audience, but practice will make it easier, says Dr Kevin Brown. Read more
Contributed by Dr Charlie Easmon specialist adviser in travel medicine and medical director at The N... Read more
Contributed by Mr Ranan DasGupta, specialist registrar and Mr Jonathon Olsburgh, consultant urologic... Read more
By Dr Helen Hosker, GP and clinical commissioning lead for stroke, NHS Manchester, and Dr Pippa Tyrr... Read more
Leo Pharma has launched Xamiol gel, a combination of calcipotriol + betamethasone, for the treatment... Read more
Bayer HealthCare has launched Xarelto (rivaroxaban) for the prevention of venous thromboembolism in ... Read more
Wyeth has launched Torisel (temsirolimus), a first-line treatment for advanced renal cell carcinoma ... Read more
Comments
Only registered users may comment. Log in now or register for a free account.